

Public declaration regarding the manufacture and use of in-house devices by health institutions

under Art. 5 (5) EU Regulation on in vitro diagnostic medical devices (EU) 2017/746 (IVDR) for in-house production of IVD in health institutions and under Art. 5 (5) EU Regulation on medical devices (EU) 2017/745 (MDR) for in-house production of MD in health institutions

Name of health institution: Labor Dr. Wisplinghoff
Address: Horbeller Str. 18 – 20, 50858 Köln, Germany

Labor Dr. Wisplinghoff declares that the devices described in the accompanying table are manufactured and/or used at *Labor Dr. Wisplinghoff* and do meet the applicable general safety and performance requirements (GSPR) of the medical devices Regulation (EU 2017/745) or of the *in vitro* diagnostic medical devices Regulation (EU 2017/746). A reasoned justification is provided in case applicable general safety and performance requirements are not fully met.

Date: 24. Juli 2025

Name, function and signature of responsible person(s):

Dr. rer. nat. Dennis Hoffmann

Technical Director



29.07.2025

Signed

Dated

Table of in-house devices:

| Device identification | Device type (IVD / MD) | Risk class of the device | Intended purpose | Applicable GSPR fully met? | Information on and justification for applicable GSPR that are not fully met |
|-----------------------------------------------------------------------------------------------------|------------------------|--------------------------|---------------------|----------------------------|-----------------------------------------------------------------------------|
| Serotonin (serum) via LC/MS/MS | IVD | B | Patient health data | Y | NA |
| 5-HIAA (plasma) via LC/MS/MS | IVD | B | Patient health data | Y | NA |
| Analysis of human genetic diseases via MLPA (multiplex ligation-dependent probe amplification) | IVD | C | Patient health data | Y | NA |
| Analysis of human genetic diseases via Sanger sequencing | IVD | C | Patient health data | Y | NA |
| Analysis of human genetic diseases via Pyrosequencing | IVD | C | Patient health data | Y | NA |
| Determination of chromosomal and genomic imbalances via array CGH | IVD | C | Patient health data | Y | NA |
| Determination of chromosomal and genomic imbalances via next generation sequencing (NGS) (Illumina) | IVD | C | Patient health data | Y | NA |
| Whole exome sequencing (WES) via NGS (Illumina) | IVD | C | Patient health data | Y | NA |
| Oncomine Focus Panel diagnostics via NGS (IonTorrent) | IVD | C | Patient health data | Y | NA |
| Somatic tumor diagnostics via NGS (IonTorrent) | IVD | C | Patient health data | Y | NA |